Wednesday November 21, 2018

‘Protein ERManI prevents HIV virus from replicating’

0
//
Republish
Reprint

New York: Researchers have discovered a protein that may slow the spread of the human immunodeficiency virus (HIV), thereby revealing a target for developing natural therapies against the deadly virus.

Picture credit: manipurupdate.com
Picture credit: manipurupdate.com

“In earlier studies, we knew that we could interfere with the spread of HIV-1, but we couldn’t identify the mechanism that was stopping the process,” said study co-author Yong-Hui Zheng, associate professor of microbiology and molecular genetics at Michigan State University in the US.

The researchers found that the protein ERManI prevents the HIV virus from replicating.

“We now know that ERManI is an essential key, and that it has the potential as a antiretroviral treatment,” Zheng noted.

Currently, there is no cure for HIV-1. Once patients have it, they have it for life. While there are antiretroviral therapies available, they can only prolong life, albeit dramatically, but they cannot cure the disease.

Current drug treatments have to be taken for a lifetime, which causes side effects and many other issues, Zheng said.

“We see a way to treat this disease by helping the body protect itself,” he noted.

While it could be decades before an ERManI-based treatment can be prescribed for HIV-1 patients, these results provide a strong path for future research involving human cells, and later, clinical tests.

The next steps will be to test if HIV resistance can be promoted by increasing ERManI levels, Zheng pointed out.

The findings were detailed in the Journal of Biological Chemistry.

(With inputs from IANS)

Click here for reuse options!
Copyright 2015 NewsGram

Next Story

Nearly 40 Individual HPV Types Linked to HIV Infection

Regarding prevention and treatment, Brown recommends the HPV vaccine, widely provided to everyone regardless of sex, gender, or sexual orientation before sexual debut, and for genital wart treatment

0
HIV
Nearly 40 individual HPV types linked to HIV infection. Pixabay

Scientists have for the first time identified 37 individual types of the human papillomavirus, or HPV, that are specifically linked to human immunodeficiency virus (HIV) infection.

The findings showed that a person with any HPV type, more than one HPV type, or high-risk HPV are more likely to test positive for HIV.

“Although most studies have shown a general link between HPV and HIV co-infection, our findings illustrate the strong relationship between individual HPV types and HIV infection,” said lead author Brandon Brown, Associate Professor at the University of California, Riverside.

“Some HPV types are more linked to cancer and others to warts. This further illustrates the potential utility of HPV vaccine for men who have sex with men and trans women, not only for HPV prevention but also possibly for HIV prevention,” Brown added.

Brown explained that previous research has shown that HPV, in general, was linked to HIV infection, but his research team looked at infection with 37 HPV types and found that individual types are linked, “which is more specific than saying HPV is linked”.

The study, published in the journal PLOS ONE, identified HPV types such as HPV16, 18, 31, 33, 35, 52, 58, linked to HIV.

HIV Aids
Computer simulations can also predict the spread of HIV: Study. Flickr

For the study, the team investigated nearly 600 men who have sex with men, or MSM, and transgender women in Lima, Peru.

Brown and his colleagues started with two groups, one with genital warts and one without, and followed participants over two years to see who contracted HIV.

Of the 571 participants who completed at least two study visits, 73 acquired HIV in two years — a 6 per cent HIV incidence rate.

Previous study with female sex workers showed that the HPV vaccine still provided protection to high-risk groups.

Also Read- Anupam Kher Wants History Not to Misjudge Manmohan Singh

Regarding prevention and treatment, Brown recommends the HPV vaccine, widely provided to everyone regardless of sex, gender, or sexual orientation before sexual debut, and for genital wart treatment.

“Even if the vaccine is not provided before sexual debut, there can be strong benefit if given at any time to prevent HPV-associated disease and also HIV,” he said.

“We know that HPV is the most common STI, and we know that HPV vaccine works to prevent chronic HPV infection. What we need now is to implement the vaccine in a better way. The availability in many other developing countries is low at best and absent at worst.” (Bollywood Country)

Comments are closed.